Literature DB >> 9753129

Suppression of kindling epileptogenesis in rats by intrahippocampal cholinergic grafts.

I Ferencz1, M Kokaia, E Elmér, M Keep, Z Kokaia, O Lindvall.   

Abstract

Selective immunolesioning of the basal forebrain cholinergic system by 192 IgG-saporin, which leads to a dramatic loss of the cholinergic innervation in cortical and hippocampal regions, facilitates the development of hippocampal kindling in rats. The aim of the present study was to explore whether grafted cholinergic neurones are able to reverse the lesion-induced increase of seizure susceptibility. Intraventricular 192 IgG-saporin was administered to rats which 3 weeks later were implanted with rat embryonic, acetylcholine-rich septal-diagonal band tissue ('cholinergic grafts') or cortical tissue/vehicle ('sham grafts') bilaterally into the hippocampal formation. After 3 months, the grafted animals as well as non-lesioned control rats were subjected to daily hippocampal kindling stimulations. In the animals with cholinergic grafts, which had reinnervated the hippocampus and dentate gyrus bilaterally, there was a marked suppression of the development of seizures as compared with the hyperexcitable, sham-grafted rats. This effect was significantly correlated to the density of the graft-derived cholinergic innervation of the host hippocampal formation. The kindling rate in the rats with cholinergic grafts was similar to that in non-lesioned controls. These results provide further evidence that the intrinsic basal forebrain cholinergic system dampens kindling epileptogenesis and demonstrate that this function can be exerted also by grafted cholinergic neurones.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753129     DOI: 10.1046/j.1460-9568.1998.00033.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  10 in total

1.  Gene therapy in epilepsy.

Authors:  Annamaria Vezzani
Journal:  Epilepsy Curr       Date:  2004 May-Jun       Impact factor: 7.500

2.  An analysis of the mean theta phase of population activity in a model of hippocampal region CA1.

Authors:  Eric A Zilli; Michael E Hasselmo
Journal:  Network       Date:  2006-09       Impact factor: 1.273

Review 3.  Commentary: the prospect of cell-based therapy for epilepsy.

Authors:  Arnold R Kriegstein; Asla Pitkänen
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

Review 4.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

5.  Intranigral transplants of a GABAergic cell line produce long-term alleviation of established motor seizures.

Authors:  Claudia G Castillo; Soledad Mendoza-Trejo; Manuel B Aguilar; William J Freed; Magda Giordano
Journal:  Behav Brain Res       Date:  2008-05-04       Impact factor: 3.332

6.  Septal nuclei enlargement in human temporal lobe epilepsy without mesial temporal sclerosis.

Authors:  Tracy Butler; Laszlo Zaborszky; Xiuyuan Wang; Carrie R McDonald; Karen Blackmon; Brian T Quinn; Jonathan DuBois; Chad Carlson; William B Barr; Jacqueline French; Ruben Kuzniecky; Eric Halgren; Orrin Devinsky; Thomas Thesen
Journal:  Neurology       Date:  2013-01-09       Impact factor: 9.910

Review 7.  Transplantation of GABA-producing cells for seizure control in models of temporal lobe epilepsy.

Authors:  Kerry Thompson
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

Review 8.  Potential new methods for antiepileptic drug delivery.

Authors:  Robert S Fisher; Jet Ho
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

9.  Septal Signaling Suppresses Seizures Through Stimulating Somatostatin Cells.

Authors:  Patrick A Forcelli
Journal:  Epilepsy Curr       Date:  2020-08-25       Impact factor: 7.500

Review 10.  New Tools for Epilepsy Therapy.

Authors:  Chiara Falcicchia; Michele Simonato; Gianluca Verlengia
Journal:  Front Cell Neurosci       Date:  2018-05-29       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.